IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways.
Specific inflammatory pathways are indicated to contribute to severe asthma but their individual involvement in the development of airway hyperresponsiveness remains unexplored. This experimental study in human small bronchi aimed to provide insight into which of the Type-2 and Type-17 cytokines cause hyperresponsiveness of airway smooth muscle. Explanted small bronchi isolated from human lung tissue and human airway smooth muscle cells (HASMC) were treated for 2 and 1 day(s) respectively with 100ng/mL of IL-4, IL-5, IL-13 or IL-17A, and contractile responses, Ca2+-mobilization, and receptor expression were assessed. Treatment with IL-13 increased the potency of histamine, carbachol and leukotriene D4 as contractile agonists. IL-4, but not IL-5 or IL-17A, also increased the potency of histamine. In HASMC, IL-13 and IL-4, but not IL-5 and IL-17A, enhanced the histamine-induced Ca2+-mobilisation that was accompanied with increased mRNA expression of histamine H1 and CysLT1 receptors. RNA sequencing of isolated bronchi confirmed the IL-13-mediated up-regulation of H1 and CysLT1 receptors, without showing an alteration of muscarinic M3 receptors. Dexamethasone had no effects on IL-13-induced hyperresponsiveness in human bronchi, the increased Ca2+-mobilisation or the enhanced receptor expression. In contrast, antagonism of the common receptor for IL-13 and IL-4 by the biologic dupilumab, prevented the effects of both IL-13 and IL-4 in human bronchi and HASMC. The glucocorticoid-insensitive hyperrresponsiveness in isolated human airways induced by IL-13 and IL-4 provides further evidence that the IL-4Rα pathway should be targeted as a new strategy for treatment of airway hyperresponsiveness in asthma.